Through collaboration, we hope to overcome some of the biggest challenges facing global health. We are passionate about helping clients in pursuit of this goal, and continuously push ourselves to do more to advance public health efforts and improve health for all.
We are committed to doing our part by harnessing our resources and expertise to identify, understand, and address unmet public health needs. We believe that by unleashing the power of Human Data Science, we can reimagine ways to address the most complex global health challenges.
And we don’t do it alone. Working in partnership with life science companies, medical researchers, government agencies, payers, nonprofit organizations, and other healthcare stakeholders, we deliver insights and solutions that make a meaningful difference in global public health.
Through collaboration, we hope to overcome some of the biggest challenges facing global health.
Leading the Way in Drug Safety: IQVIA formed a novel alliance with the FDA Center for Biologics Evaluation and Research to monitor and evaluate the safety and effectiveness of various vaccines, blood products, and other biologics. For this important public health collaboration, IQVIA worked with the Observational Health Data Science and Informatics initiative and its world-class team of healthcare experts and unique data assets from Columbia University, Stanford University, Georgia Institute of Technology, University of California, Los Angeles and the Regenstrief Institute at the Indiana University School of Medicine to enhance the function and outputs of the initiative.
Fighting the Opioid Epidemic: IQVIA partnered with the American Medical Association’s Task Force to Reduce Opioid Abuse to help reverse the nation’s opioid epidemic and provided valuable insight into the ongoing efforts to combat this public health crisis. Our data and analyses helped illustrate the effects of legislation regarding opioids.
Bridging Oncology Gaps: IQVIA created the Collaboration for Oncology Data in Europe (CODE) with life science partners to maximize the value of cancer treatment while helping to facilitate access to innovative new therapies. CODE is developing an Oncology Data Network to harness valuable information about anti-cancer medicines, which will benefit oncologists, pharmacists, patients, and health systems.
Addressing Antibiotic Resistance: IQVIA collaborated with the U.S. Centers for Disease Control and Prevention and supported White House efforts to combat the overuse and misuse of antibiotics. Information and analysis identified significant regional and local variability in antibiotic use across the United States. The findings shed light on the driving factors behind the rising number of drug-resistant bacteria strains to better inform ongoing prevention efforts.
Assessing Disease Burden, Enabling Innovation: Tuberculosis is a major global public health challenge and India accounts for more than a quarter of these cases on an annual basis. As part of an effort funded by the Bill and Melinda Gates Foundation, IQVIA provided crucial information about tuberculosis managed by the private sector to enable understanding of the true disease burden in the country, and around the world. The work revealed significantly higher rates of tuberculosis than had been previously recognized, as well as prospective causes, which can inform preventative protocols going forward.
Malaria Access in Action: Most malaria-endemic countries lack the ability to monitor the relationship between disease burden and the national supply and quality of critically needed medicines. To address this challenge, we collaborated with the Medicines for Malaria Venture to consolidate data flow and enable the Uganda National Drug Authority to complete the development of a system for monitoring pharmaceutical use at a national level.
Enabling Alzheimer’s Insights: European Prevention of Alzheimer's Dementia (EPAD) is a public-private consortium designed to better understand the early stages of Alzheimer’s disease and prevent dementia before symptoms occur. EPAD selected IQVIA to oversee a longitudinal study of 6,000 non-identified patients that enables researchers to track development of Alzheimer’s disease symptoms.
Research by the Institute Recognizing the potential to contribute to the advancement of human health globally, IQVIA created the IQVIA Institute for Human Data Science to deliver objective, timely and relevant insights and research that accelerate understanding and innovation critical to sound decision making and improved human outcomes. Through collaboration with the Institute, researchers and students have access to a broad range of proprietary databases and tools to support independent research and discovery work. Research by the Institute is published in reports which are available without charge. These reports are widely cited by in the media and by other researchers in their peer-reviewed research.
Shared Learnings: We work with clients and partners to share the learnings from their work, often through the hundreds of peer-reviewed publications and medical articles as well as thousands of general news articles where the work was cited.
Furthering Research: We partner with academic research organizations around the world to provide “gifts in kind” data resources and analysis to further their research endeavors. Over the past five years, the estimated value of this pro bono and and deeply discounted support has exceeded $50 million.
We are on the front-lines of the global public health conversation through ongoing work with nonprofit organizations, government agencies, patient advocacy groups, and other healthcare stakeholders. We are setting the agenda for public discussion of healthcare topics—ranging from biosimilar sustainability to orphan drug development and biopharmaceutical innovation—with regular publication of original, independent reports.
Access to infrastructure and standards: IQVIA is a preferred provider to a consortium of 14 global health Product Development Partnerships, funded in part by the Bill and Melinda Gates Foundation. By partnering with the consortium members, IQVIA provides access to our global clinical development infrastructure and standards, particularly in the areas of infectious diseases such as HIV, malaria and tuberculosis.
Patient empowerment: We have a long-standing commitment to pursue patient engagement strategies to better educate and include patients in the evolving clinical research environment. This important work is enabling people to receive health services, clinical trial education and active connections to clinical research programs across the globe.
Regulatory evolution: IQVIA works alongside regulators and policy makers to foster a regulatory environment that advances human health and the conduct of clinical trials. We were the only company of its kind to actively participate in the development and passage of the 21st Century Cures Act, including testifying before the U.S. House Energy and Commerce Health Subcommittee on the topic of “Modernizing of Clinical Trials.” Our team in India also contributed to strengthening the regulatory infrastructure within that country, including the creation of a scientific framework for clinical trials.
We are actively involved in the CEO Roundtable on Cancer, a nonprofit organization that works to develop and implement initiatives that reduce the risk of cancer, and are currently designated as a “Gold Standard Employer.”
Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?
We're available during standard business hours.
U.S. Toll-Free only
+1 866 267 4479
For international call please find a number in our toll-free list.
The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.
Please note that forms have been updated on SC9 PROD, it may be good to update the SC9 DEV forms with SC9 PROD.